RxDoctor Payments DataLook up a doctor →

James Strauss

Medical Oncology · Dallas, TXNPI 1770525933

Payments from drug & device makers

$9,089,260in general payments, 2019–2025

Across 1,283 payments — averaging $7084.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$3.2M
  • Pfizer$1.2M
  • Alkermes, Inc.$1M
  • GSK$922K
  • Takeda Pharmaceuticals U.S.A., Inc.$665K
  • Epizyme, Inc.$438K
  • plus $1.6M from 13 others

What the payments were for

  • Food & beverage$23100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merck195$3,212,233
Pfizer44$1,185,249
Alkermes, Inc.189$1,029,204
GSK205$922,411
Takeda Pharmaceuticals U.S.A., Inc.159$664,667
Epizyme, Inc.97$437,832
Daiichi Sankyo Inc.107$381,053
Gilead65$279,517
Array Biopharma Inc77$210,253
Taiho Oncology, Inc.99$195,554
Novartis6$150,754
E.r. Squibb & Sons, L.L.C.4$113,187
Astrazeneca UK Limited6$107,000
Genentech, Inc.14$92,842
Bayer9$69,247
Seagen Inc.1$24,600
Macrogenics, Inc.4$13,627
Restor3d, Inc.1$23
AstraZeneca1$11

How this compares

$9,089,260 in reported general payments places this provider in the 90th percentile of 495 medical oncology providers in Texas.

See all medical oncology providers in Texas →

Other medical oncology in Dallas

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →